Exane Derivatives’s Crown Castle CCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$168 Hold
1
﹤0.01% 685
2022
Q1
$185 Hold
1
﹤0.01% 966
2021
Q4
$209 Hold
1
﹤0.01% 840
2021
Q3
$173 Hold
1
﹤0.01% 1014
2021
Q2
$200 Sell
1
-2
-67% -$374 ﹤0.01% 1015
2021
Q1
$516 Hold
3
﹤0.01% 794
2020
Q4
$478 Sell
3
-48
-94% -$7.79K ﹤0.01% 744
2020
Q3
$8.49K Sell
51
-692
-93% -$114K ﹤0.01% 473
2020
Q2
$124K Buy
+743
New +$120K 0.03% 265
2020
Q1
Sell
-1,490
Closed -$215K 708
2019
Q4
$215K Sell
1,490
-23
-2% -$3.14K 0.04% 250
2019
Q3
$210K Buy
1,513
+1,430
+1,723% +$198K 0.04% 251
2019
Q2
$10.8K Sell
83
-1,232
-94% -$158K ﹤0.01% 451
2019
Q1
$168K Buy
+1,315
New +$154K 0.03% 234
2018
Q3
Sell
-1
Closed -$108 701
2018
Q2
$108 Hold
1
﹤0.01% 611
2018
Q1
$112 Hold
1
﹤0.01% 546
2017
Q4
$111 Sell
1
-6,268
-100% -$676K ﹤0.01% 540
2017
Q3
$627K Sell
6,269
-64
-1% -$6.54K 0.12% 124
2017
Q2
$634K Buy
+6,333
New +$622K 0.14% 128
2016
Q4
Sell
-8,192
Closed -$772K 653
2016
Q3
$772K Buy
+8,192
New +$788K 0.12% 115

Other funds holding CCI

Exane Derivatives's CCI Position: Q2 2022 in Review

Exane Derivatives held its Crown Castle (CCI) position steady in Q2 2022 at 1 share worth $168. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Exane Derivatives first reported a position in CCI in Q3 2016 and has held it in 19 quarters since. The position peaked at $772K in Q3 2016. 1,350 funds tracked by Wall St. Rank hold CCI as of Q2 2022.

  • Exane Derivatives held 1 share of Crown Castle worth $168 as of Q2 2022.
  • Exane Derivatives left its Crown Castle share count unchanged in Q2 2022.
  • Crown Castle made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #685 holding.
  • Exane Derivatives first reported a position in Crown Castle in Q3 2016 and has held it in 19 quarters since.
  • Exane Derivatives's Crown Castle position peaked at $772K in Q3 2016.
  • 1,350 funds tracked by Wall St. Rank held Crown Castle as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.